Form 4: Guardant Health's Co-CEO Helmy Eltoukhy Reports Acquisition of Restricted Stock Units

Helmy Eltoukhy, Co-Chief Executive Officer of Guardant Health, Inc., reports the acquisition of restricted stock units on March 12, 2025.

Summary

• On March 12, 2025, Helmy Eltoukhy, Co-Chief Executive Officer of Guardant Health, Inc., acquired restricted stock units (RSUs).
• A total of 19,258 RSUs were granted, vesting in four equal installments on the last day of each calendar quarter in 2025.
• Additionally, 116,010 RSUs were granted, with 33% vesting on January 1, 2026, and the remaining 67% vesting in equal quarterly installments over the subsequent two years.
• Following these transactions, Eltoukhy directly owns 19,258 and 116,010 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive event.

Positives

• The grant of restricted stock units to the Co-CEO aligns his interests with those of the shareholders.

Industry Context

This is a standard practice for incentivizing and retaining key executives in publicly traded companies, particularly in the biotech and healthcare sectors.

Comparison to Industry Standards

• Stock-based compensation is a common practice among publicly traded companies, especially in the technology and biotechnology sectors.
• Companies like Illumina, Roche, and Exact Sciences also utilize stock options and restricted stock units to incentivize their executives.
• The vesting schedules described are fairly standard, with quarterly or annual vesting periods being typical.

Stakeholder Impact

• Shareholders may view this as a positive sign, indicating that the Co-CEO's interests are aligned with theirs.
• Employees may see this as a sign of stability and commitment from the leadership team.

Key Dates